Historique
Périodique
Factors associated with 12 months continuous heroin abstinence: findings from the australian treatment outcome study (ATOS)
(Facteurs associés à l'abstinence ininterrompue d'héroïne durant 12 mois. Données issues de l'ATOS, Australian Treatment Outcome Study, Etude Australienne des Résultats de Traitement)
Auteur(s) :
DARKE, S. ;
ROSS, J. ;
TEESSON, M. ;
ALI, R. ;
COOKE, R. ;
RITTER, A. ;
LYNSKEY, M.
Année
2005
Page(s) :
255-263
Langue(s) :
Anglais
Refs biblio. :
37
Domaine :
Drogues illicites / Illicit drugs
Thésaurus mots-clés
EVALUATION
;
ETUDE LONGITUDINALE
;
DEPENDANCE
;
HEROINE
;
ABSTINENCE
;
DUREE
;
TRAITEMENT
;
TRAITEMENT RESIDENTIEL
;
INJECTION
;
DEVENIR
Thésaurus géographique
AUSTRALIE
Note générale :
Journal of Substance Abuse Treatment, 2005, 28, (3), 255-263
Note de contenu :
graph. ; tabl.
Résumé :
ENGLISH :
Aims: To determine the role of treatment and client characteristics associated with the achievement of continuous heroin abstinence. Design: Longitudinal cohort study. Setting: Sydney and Adelaide, Australia. Participants: 570 heroin users re-interviewed at 12 month follow-up for the Australian Treatment Outcome Study (ATOS). Findings: Continuous heroin abstinence was reported by 14% of participants. Continuous abstinence was associated with no previous treatment history, having entered treatment at baseline, and cumulative treatment exposure over the follow-up period. Longer retention times in index maintenance and residential rehabilitation treatments, but not detoxifications, were most associated with abstinence. At baseline, abstinent participants were more Likely to have been classified as treatment ready, or to have used heroin less frequently; and less likely to have been daily injectors, using cocaine or criminally involved. Conclusions: Approximately 14% of ATOS participants achieved continuous heroin abstinence over 12 months. Such an achievement was strongly associated with a longer "dose" of treatment, and with more treatment stability over the follow-up period. (Editor's abstract.)
Affiliation :
National Drug and Alcohol Research Centre, University of New South Wales, NSW, 2052. E-mail : s.darkeunsw.edu.au
Australie. Australia.
Australie. Australia.